ArticleDiabetes, obesity & metabolism2016
Prevention of antibiotic-associated metabolic syndrome in mice by intestinal alkaline phosphatase.
Article in Diabetes, obesity & metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Machine Learning Models for High-Throughput Screening of Obesogens Based on Pathway Network.Environment & health (Washington, D.C.) · 2026Article
- Protective Effect of Alkaline Phosphatase Supplementation on Infant Health.Foods (Basel, Switzerland) · 2022Review
- Intestinal Alkaline Phosphatase: A Review of This Enzyme Role in the Intestinal Barrier Function.Microorganisms · 2022Review
- Antibiotic Azithromycin inhibits brown/beige fat functionality and promotes obesity in human and rodents.Theranostics · 2022Article
- Targeting the Intestinal Barrier to Prevent Gut-Derived Inflammation and Disease: A Role for Intestinal Alkaline Phosphatase.Visceral medicine · 2021Review
- Obesity, Early Life Gut Microbiota, and Antibiotics.Microorganisms · 2021Review
- Article
- Article
- Intestinal alkaline phosphatase modulation by food components: predictive, preventive, and personalized strategies for novel treatment options in chronic kidney disease.The EPMA journal · 2020Review
- Targeting the gut to prevent sepsis from a cutaneous burn.JCI insight · 2020Article
- Transcriptomic signature of gut microbiome-contacting cells in colon of spontaneously hypertensive rats.Physiological genomics · 2020Article
- Propionate-Producing Consortium Restores Antibiotic-Induced Dysbiosis in a DynamicFrontiers in microbiology · 2019Article
- Effect of dietary additives on intestinal permeability in bothDisease models & mechanisms · 2018Article
- Relative variations of gut microbiota in disordered cholesterol metabolism caused by high-cholesterol diet and host genetics.MicrobiologyOpen · 2017Article
- Early life antibiotic exposure affects pancreatic islet development and metabolic regulation.Scientific reports · 2017Article
- Antibiotic Exposure in Early Life Increases Risk of Childhood Obesity: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2017Article
- The Role of Intestinal Alkaline Phosphatase in Inflammatory Disorders of Gastrointestinal Tract.Mediators of inflammation · 2017Review
- Microbiome-Metabolome Responses to a High-Grain Diet Associated with the Hind-Gut Health of Goats.Frontiers in microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Funding
Abstract
aimsTo examine whether co-administration of intestinal alkaline phosphatase (IAP) with antibiotics early in life may have a preventive role against metabolic syndrome (MetS) in mice.
methodsA total of 50 mice were allocated to four treatment groups after weaning. Mice were treated with azithromycin (AZT) ± IAP, or with no AZT ± IAP, for three intermittent 7-day cycles. After the last treatment course, the mice were administered a regular chow diet for 5 weeks and subsequently a high-fat diet for 5 weeks. Body weight, food intake, water intake, serum lipids, glucose levels and liver lipids were compared. 16S rRNA gene pyrosequencing was used to determine the differences in microbiome composition.
resultsExposure to AZT early in life rendered mice susceptible to MetS in adulthood. Co-administration of IAP with AZT completely prevented this susceptibility by decreasing total body weight, serum lipids, glucose levels and liver lipids to the levels of control mice. These effects of IAP probably occur as a result of changes in the composition of specific bacterial taxa at the genus and species levels (e.g. members of Anaeroplasma and Parabacteroides).
conclusionsCo-administration of IAP with AZT early in life prevents mice from susceptibility to the later development of MetS. This effect is associated with alterations in the composition of the gut microbiota. IAP may represent a novel treatment against MetS in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.